Development of the new therapeutic antibodies for mesothelioma

我们先前研制了抗人膜性C-ERC/间皮蛋白的单抗22A31。在这项研究中，我们证实了22A31对人间皮瘤细胞系小鼠皮下或腹膜内移植的抗增殖活性。小鼠瘤内或腹膜内注射22A31后，均显示对间皮瘤细胞增殖的抑制作用。血清分泌型N-ERC/Mesothelin的浓度反映了肿瘤的增殖程度，对预测治疗效果有重要意义。

We previously developed anti-human membranous C-ERC/Mesothelin monoclonal antibody 22A31. In this study, we proved 22A31 to have anti-proliferative activity for human mesothelioma cell lines transplanted subcutaneously or intraperitonealy in mice. 22A31 was injected to mice via intratumoral or intraperitoneal routes, and it showed the inhibitory effect for the proliferation of mesothelioma cells in all experiments. Serum concentration of the secretory N-ERC/Mesothelin reflected the extent of the tumor-proliferation, and seemed to be significant in the prediction of the effect of treatment.